Abstract
Cell therapy using T cells expressing chimeric antigen receptors (CARs) has already revolutionized the treatment of some B-cell leukemias and lymphomas. However, for other hematological malignancies and solid tumors, the long-term clinical response rate is low (~ 20%) or nonexistent. Recent studies indicate that the main causes of these failure cases are the anergy and low persistence of …